(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

A Shropshire hospital trust says patients with prostate cancer are benefitting from greater survival rates thanks to a ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

The Gleason score reliably predicts lethal prostate cancer for up to 25 years after diagnosis. High-grade prostate cancers progress rapidly in the short term, while lower grade tumors can still lead ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...